FDA Approvals, News & UpdatesLymphoma

Adcetris Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma

December 2022 Vol 8 No 6

In November 2022, the FDA approved Adcetris (brentuximab vedotin; from Seagen), a CD30-directed antibody–drug conjugate, in combination with a chemotherapy regimen for pediatric patients aged 2 years or older with high-risk classical Hodgkin lymphoma who have not received previous therapy. This is the first approval of Adcetris for pediatric patients. It was previously approved for this condition in adults.

The FDA approved Adcetris plus chemotherapy for young patients based on results of a randomized, open-label, actively controlled clinical trial that included 600 patients with classical Hodgkin lymphoma. The patients were divided into 2 groups to receive either Adcetris plus chemotherapy or chemotherapy alone.

The average time of event-free survival, defined as the time from randomization to the earliest of disease progression or disease relapse (coming back), second cancer, or death from any cause, was not reached in either group, meaning that most patients continued to benefit from their treatment and did not have disease progression or other serious events.

The most common serious side effects with Adcetris plus chemotherapy in pediatric patients were neutropenia, anemia, thrombocytopenia, febrile neutropenia, stomatitis, and infection.

Recommended For You
LymphomaFinancial Support
Drugs for Lymphoma
Find financial assistance programs available for lymphoma drugs.
You Only Live T-W-I-C-E: A Cancer Warrior’s Motto
By Steffi Dawn Ilagan
Receiving a diagnosis of stage IIIB diffuse large B-cell non-Hodgkin lymphoma at age 26 at the start of COVID-19 meant that Steffi Ilagan had to sideline a lot of her plans. Her story illuminates the meaning of “T-W-I-C-E” when facing cancer.
Last modified: December 15, 2022

Subscribe to Conquer: the journey informed

Receive timely cancer news & updates, patient stories, and more.

Race or Ethnicity
Profession or Role
Primary Interest
Other Interests